id,file,title,caption,rows
T1_Raw_Source_And_Integrity,T1_Raw_Source_And_Integrity.csv,Raw data version and provenance,Provider-verified DepMap 24Q4 v1 sources downloaded afresh for this run; no historical result artifact was an input.,7
T2_Primary_PanCancer_C1_BY,T2_Primary_PanCancer_C1_BY.csv,Primary pan-cancer C1 discoveries,"A=conditioned mutant; B=additional mutation; X=target gene. HC3 β is A+B versus A-only CRISPR effect, negative is stronger dependency; BY q<=0.05.",83
T3_Original_Refit_Robustness,T3_Original_Refit_Robustness.csv,C2 sensitivity and refit stability,"Selected context refits with model/lineage deletions; unestimable refits retained. This is internal statistical stability, not independent replication.",546
T4_Reactome_ORA_GSEA,T4_Reactome_ORA_GSEA.csv,Reactome functional enrichment,"Original release-locked Reactome 98 ORA and preranked GSEA, context-wise BH; associations do not prove mediation.",360965
T5_Expression_CN_Molecular,T5_Expression_CN_Molecular.csv,Molecular expression and copy-number association,Unadjusted A+B versus A-only expression/copy-number contrasts where observed; not causal validation.,1092
T6_C3_Four_Group_Original_Coverage,T6_C3_Four_Group_Original_Coverage.csv,C3 genetic four-group estimability and negative evidence,All originally eligible C3 four-group gene-effect contexts; low genotype-arm counts and nonestimable models remain visible.,2056
T7_PRISM_Conditional_Drug_Response,T7_PRISM_Conditional_Drug_Response.csv,PRISM drug response A+B vs A-only,"All matched fresh-C1-target-drug candidates (including null, discordant, and underpowered); robust HC3, within-family BH/BY. Lower PRISM AUC indicates higher sensitivity.",62
T8_PRISM_Strict_AxB_Interaction,T8_PRISM_Strict_AxB_Interaction.csv,PRISM strict four-genotype interaction,A+B interaction is secondary; FDR applies over all estimable candidate tests. Absence of significant interaction does not invalidate conditional association.,62
T9_PRISM_AB_vs_Bonly,T9_PRISM_AB_vs_Bonly.csv,PRISM drug response A+B vs B-only,Supplementary comparison among B-mutated models. Does not define the primary directional co-mutation estimand.,62
T10_TCGA_Patient_CoMutation_Prevalence,T10_TCGA_Patient_CoMutation_Prevalence.csv,Selected TCGA cohort mutation co-occurrence,"Selected cancer studies only, any reported nonsilent mutation, not equivalent to DepMap damaging/hotspot. Not patient drug response evidence.",168
T11_Integrated_Candidate_Evidence,T11_Integrated_Candidate_Evidence.csv,Integrated prioritization and limitations,"Cross-assay observational evidence, compound-target annotation, TCGA descriptive co-occurrence; no causal synergy or validation inferred.",83
ST1_Expression_Pathway_Activity,ST1_Expression_Pathway_Activity.csv,Expression-derived oncogenic pathway activity,Mean z-scored log1p TPM of measured signature genes; not pathway activation or causal mediation proof.,7938
T12_Noncausal_Interpretation_And_Failed_Evidence,T12_Noncausal_Interpretation_And_Failed_Evidence.csv,Limitations and underpowered evidence,Negative/unavailable results are recorded; no independent/wet-lab validation claims.,11
Experiment_Claim_to_Evidence_Registry,Experiment_Claim_to_Evidence_Registry.csv,Claim-evidence mapping,Counts measured freshly at run time; none copied from past experiments.,6